« Return to News | Drug Sponsors

Nycomed and Almirall partner to market COPD drug

Thursday, May 5, 2011 11:54 AM

Nycomed and Almirall will become marketing partners for the chronic obstructive pulmonary disease (COPD) treatment Daxas. The two firms have entered into a co-branding agreement covering Spain for Daxas (roflumilast), Nycomed's once-daily COPD tablet, according to Pharma Times.

Under the terms of the agreement, Nycomed will receive an undisclosed upfront fee from Almirall, which will be exclusively promoting a second brand of the phosphodiesterase 4 (PDE4) enzyme inhibitor.

Almirall's chief operating officer Luciano Conde said the deal "reinforces our portfolio with a first-in-class product and allows us to leverage our respiratory capabilities and expertise." He added that the product "has a strong strategic fit in our business and is fully complementary with other bronchodilator treatments in COPD such as our R&D product aclidinium bromide which is expected to be filed this year."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.